POS0083-PARE GETTING RESEARCH INTO THE HANDS OF PEOPLE LIVING WITH RHEUMATOID ARTHRITIS: A NOVEL APPROACH FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH)
Authors: L. Proulx, D. Richards, J. Coish, O. Schieir, J. Kern, E. Keystone, J. Pope, C. Thorne, G. Boire, S. J. Bartlett, G. Hazlewood, D. Tin, C. A. Hitchon, M. E. Veilleux, M. C. Beaulieu, V. Bykerk
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> The Canadian Early Arthritis Cohort (CATCH) is the only Canada-wide, multi-centre, early arthritis cohort study that is following people with new onset inflammatory or rheumatoid arthritis (RA) over time. Translating research knowledge from evidence to action is important especially to patients who live with RA to help them actively be part of shared decision making. Knowledge translation (KT) is the process of taking research findings and making them understandable and applicable to different audiences, like patients and the public, however patients and the public are often left out of this process. <h3>Objectives:</h3> Our objective was to develop a novel video-series developed with patient/public engagement along with our other KT products. <h3>Methods:</h3> KT specialists who live with RA (LP, DPR) developed a KT plan guided by the Knowledge to Action Framework (K2A) focused on patients as the target audience and worked with the core project team (JC, OS, VB). The KT plan included a list of topics that might be of interest to people with RA, CATCH research, and KT strategies (e.g. videos). Patient input (topics for videos, questions) was sought with Twitter/X polling and members of the Scientific Advisory Committee (EK, JP, CT, GB, SB, LB, GH, DT, CH) and people with RA (MEV, MCB) were consulted about this input. KT specialists filmed the videos in person, developed plain language summaries of research results, and did outreach to patient organizations to compile evidence-based resources by topic. The videos were disseminated on various social media platforms, like Twitter/X, YouTube, Instagram, and the CATCH website. <h3>Results:</h3> We have developed 100, two-to-three-minute English and French videos on a range of topics of interest to people living with RA, such as: living with and facts about RA; preventing infections/ vaccines; work; and flares, pain, and fatigue. We measured the KT uptake with social media and website traffic data: the YouTube channel has 96,324 video views and 548 subscribers, the Twitter/X platform has over 1000 followers, and Instagram has recently been launched and has 95 followers. New relationships have also been established with patient organizations and health care professional organizations in Canada. <h3>Conclusion:</h3> Our KT approach addresses an important gap by sharing research knowledge with patients and the public through accessible, engaging, and user-friendly videos. Future efforts include adapting the KT plan to particular health care professionals' and policy makers and measuring the impact of KT plans on patients' knowledge and behaviour. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Laurie Proulx: None declared, Dawn Richards: None declared, Jaime Coish: None declared, Orit Schieir: None declared, Jenny Kern: None declared, Edward Keystone AbbVie, Amgen, Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi-Genzyme, Samsung Bioepsis, AbbVie, Amgen, Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi-Genzyme, Samsung Bioepsis, Amgen, Merck, Pfizer Pharmaceuticals, Janet Pope UCB, AbbVie, Actelion, Amgen, Bayer, BMS, Eicos Sciences, Eli Lilly &amp; Company, Emerald, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, AbbVie, BMS, Eli Lilly &amp; Company, Merck, Roche, Seattle Genetics, UCB, Carter Thorne Medexus/ Medac, AbbVie, Centocor, Janssen, Medexus; Novartis Pfizer; Sandoz; Sanofi; Amgen, Celgene, Lilly, Pfizer, Gilles Boire Abbvie, BMS, Orimed Pharma, Viatris, Abbvie, BMS, Gilead, Janssen, Lilly, Mylan, Novartis, Pfizer, Samsung Bioepis, Sanofi, Teva, Viatris, BMS, Eli Lilly, Janssen, Merck, Pfizer, Susan J. Bartlett Pfizer, UCB, Lilly, Novartis, Merck, Janssen, AbbVie, Glen Hazlewood: None declared, Diane Tin: None declared, Carol A Hitchon Astra-Zeneca, Pfizer, UCB Public Health Agency of Canada, Research Manitoba, Health Sciences Centre Foundation, Marie-Eve Veilleux: None declared, Marie-Claude Beaulieu: None declared, Vivian Bykerk BMS, Janssen, Gilead, Pfizer, Sanofi Aventis, UCB, Amgen, BMS; The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Pfizer Canada- Founding sponsor since 2007; AbbVie Corporation since 2011; Hoffman La Roche Limited since 2011; Sandoz Biopharmaceuticals Canada since 2019; Fresenius Kabi Canada and Organon Canada since 2021; Viatris Canada, Jamp Pharma (BIOJAMP), Nordic Pharma, and Celltrion Healthcare Canada since 2023. Previous funding from Amgen Canada (2007-22); Janssen Canada (2011-16); UCB Canada and Bristol-Myers Squibb Canada (2011-18); Medexus Pharmaceuticals (2013-2022); Sanofi Genzyme (2016-17); Eli Lilly Canada (2016-20); Merck Canada (2017-21) and, Gilead Sciences Canada (2020-21).